James J Schlesselman
Overview
Explore the profile of James J Schlesselman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
4864
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Vandenbroucke J, von Elm E, Altman D, Gotzsche P, Mulrow C, Pocock S, et al.
Int J Surg
. 2014 Jul;
12(12):1500-24.
PMID: 25046751
Much medical research is observational. The reporting of observational studies is often of insufficient quality. Poor reporting hampers the assessment of the strengths and weaknesses of a study and the...
3.
Raez L, Papadopoulos K, Ricart A, Chiorean E, DiPaola R, Stein M, et al.
Cancer Chemother Pharmacol
. 2012 Dec;
71(2):523-30.
PMID: 23228990
Purpose: This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and maximum tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy-D-glucose (2DG) in combination with docetaxel, in patients...
4.
Mehta D, Foon K, Redner R, Raptis A, Agha M, Hou J, et al.
Leuk Res
. 2011 Feb;
35(7):885-8.
PMID: 21315448
The most effective regimen for acute myeloid leukemia (AML) patients who do not achieve complete remission (CR) after two different courses of front-line chemotherapy has not been established. We therefore...
5.
Mchayleh W, Foon K, Redner R, Sehgal R, Raptis A, Agha M, et al.
Cancer
. 2010 Jun;
116(12):3001-5.
PMID: 20564405
Background: Elderly patients with acute myeloid leukemia (AML) are generally unable to withstand the rigors of intensive induction chemotherapy and its attendant complications. Gemtuzumab ozogamicin (GO) is an immunoconjugate that...
6.
Mchayleh W, Sehgal R, Redner R, Raptis A, Agha M, Natale J, et al.
Leuk Lymphoma
. 2009 Oct;
50(11):1848-53.
PMID: 19860628
The most effective regimen for patients with acute myeloid leukemia (AML) who do not achieve complete remission (CR) after one course of cytarabine and an anthracycline has not been extensively...
7.
Brell J, Matin K, Evans T, Volkin R, Kiefer G, Schlesselman J, et al.
Oncology
. 2009 Mar;
76(4):270-4.
PMID: 19258727
Background: There is no standard second-line therapy for advanced pancreatic cancer (APC). We evaluated the epidermal growth factor receptor (EGFR) inhibitor gefitinib and docetaxel in a phase II study following...
8.
Vandenbroucke J, von Elm E, Altman D, Gotzsche P, Mulrow C, Pocock S, et al.
Gac Sanit
. 2009 Mar;
23(2):158.
PMID: 19249134
Much medical research is observational. The reporting of observational studies is often of insufficient quality. Poor reporting hampers the assessment of the strengths and weaknesses of a study and the...
9.
Vandenbroucke J, von Elm E, Altman D, Gotzsche P, Mulrow C, Pocock S, et al.
Epidemiology
. 2007 Dec;
18(6):805-35.
PMID: 18049195
Much medical research is observational. The reporting of observational studies is often of insufficient quality. Poor reporting hampers the assessment of the strengths and weaknesses of a study and the...
10.
Vandenbroucke J, von Elm E, Altman D, Gotzsche P, Mulrow C, Pocock S, et al.
PLoS Med
. 2007 Oct;
4(10):e297.
PMID: 17941715
Much medical research is observational. The reporting of observational studies is often of insufficient quality. Poor reporting hampers the assessment of the strengths and weaknesses of a study and the...